Hudig: Tumor Immunology Flashcards

1
Q

Are tumors considered self or non-self?

A

tumors are similar to self and have few antigens, so immune responses to tumors are limited

**don’t generate IL-1, TNFalpha, and signal 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Give 3 reasons why immune responses to tumors are “weak.”

A
  1. tumor antigens are tolerated as self
  2. persistent immune responses lead to T cell exhaustion
  3. tumors create a suppressive environment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Tumorgenesis induces T cell (blank) – lack of inflammation and signal 2

A

anergy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 3 E’s on tumor immunity?

A

elimination: immunosurveillance of highly antigenic neoplasms
equilibrium: tumor growth and immune killing both occur
escape: tumor loses antigens, secretes inhibitory factors, grows out of control, etc…

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What phase is this: when tumors arise in the tissue, a number of immune cells can recognize and eliminate them

A

elimination phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What phase is this: variant tumor cells arise that are more resistant to being killed; over time, a variety of different variants emerge

A

equilibrium phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What phase is this: eventually, one variant may escape the killing mechanism or recruit regulatory cells to protect it and spread unchallenged

A

escape phase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tumor immunity is usually (blank) for individual tumors

A

specific

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the difference between tumor specific antigens and tumor associated antigens?

A

tumor specific antigens are found on tumors but not on normal cells (ex: papiloma viral ag’s in MHCI)
tumor associated antigens are found on both tumor and normal cells (ex: MAGE in melanoma or HER2 on breast cancer cells0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are these: products of mutated oncogenes and tumor suppressor genes

A

tumor specific antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are these examples of:
mutated p53 tumor suppressor protein
unique Ig receptors on B cell lymphomas

A

tumor specific antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are these: over-expressed and abnormally expressed proteins

A

tumor associated antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Give some examples of tumor associated antigens

A

MAGE in melanoma (usu only expressed in the testis and placenta)
HER 2 in breast cancer (epidermal growth factor receptor)
EGFR is expressed at a higher level on cancer cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

5 antigens associated with myeloma

A
cyclin-dependent kinase 4
Beta-catenin
MAGE1
Tyrosinase
GP100/TRP2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

This antigen is seen in squamous cell carcinoma

A

caspase 8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

This antigen is seen in hepatoma

A

Alpha-fetoprotein

17
Q

This antigen is seen in Burkitt’s lymphoma

18
Q

Why are melanomas used for trials of anti-tumor immunity?

A

melanoma has 5 antigens, so it is easily recognizable

19
Q

What are the 5 cell types active in tumor immunity

A

CD8 T cell (responds to tumor Ags in MHCIs)
TH1 T helper cells (to activate macrophages)
activated macrophages (to kill or increase cytokines)
NK cells (for immunosurveillance and to kill tumor cells if they’ve lost their MHC expression later)
T regs

20
Q

What do NK cells do for tumors early on? Late in the game?

A

early: they are involved in immunosurveillance looking for whacky antigens
late: kill tumor cells if tumors lose MHCI

21
Q

If an NK cell encounters a tumor cell that does not have MHCI molecules on it, it cannot stimulate a negative signal. So, what happens?

A

NK cell will become activated, release its contents and kill the cell

**On-off balance favors “off”. Lack of MHC means no more “off” so NK cell stays “on” and kills.

22
Q

List three ways in which the tumor microenvironment reduces tumor immunity (killing of tumors)

A
  1. low immunogenicity (no peptide:MHC ligand, no co-stimulatory molecules on tumor cells)
  2. tumor is treated as self (tumor antigens are taken up and presented by APCs in absence of co-stimulation leading to tolerized T cells)
  3. tumors induce immune suppression by secreting factors like IL-10 and TGF-beta which inhibit T cells directly
23
Q

What does CTLA-4 do for tumor cells?

A

it down-regulates T cell division

24
Q

What can persistent antigen presentation by tumor cells do to CTL’s?

A

cause immune exhaustion

25
Immunotherapies for cancers can either be passive or enhance active immunity. What is the difference?
passive monoclonalAb: block growth factor receptors with an antibody active immunity: increase immunity against tumor cells, adoptive transfer of CTLs, vaccines to boost immunity
26
Herceptin, Erbitux, and Rituxan are all monoclonal antibodies used in immunotherapy against cancer cells. What is the major effective mechanism for these mAbs?
antibody dependent cell-mediated cytotoxicity
27
chimeric monoclonal antibody used against CD20 in non-Hodgkins lymphoma
rituximab
28
monoclonal anti-HER2 antibody used in breast cancer
Herceptin (trastuzumab)
29
(blank), a receptor of the EGF receptor family, is expressed on both normal tissue and 20-30% of all breast carcinomas.
HER2
30
What are 2 NEW means of manipulating the anti-tumor response?
1. anti-CTLA-4 to increase tumor-specific T cells | 2. anti-programmed death receptor 1 to keep T helpers and CTLs alive and functioning
31
Two mAbs used together to increase T cell activities?
ipilimumab + nivolumab (anti-CTLA4 and anti-PD1)
32
How can you overcome anergy by tumor cells?
individual tumor cells can be transfected with B7 co-stimulatory molecules and used to re-stimulate T cells
33
Tumors have tumor-specific antigens, but most tumors are weakly (blank).
immunogenic